Drug Profile
Canagliflozin - Johnson & Johnson/Mitsubishi Tanabe Pharma Corporation
Alternative Names: Canagliflozin-hydrate; Canaglu; Invokana; JNJ-28431754; Sulisent; TA-7284Latest Information Update: 20 Mar 2024
Price :
$50
*
At a glance
- Originator Tanabe Seiyaku
- Developer Daiichi Sankyo Company; Janssen; Johnson & Johnson; Mitsubishi Tanabe Pharma Corporation; Miyazaki University School of Medicine; Mundipharma Medical Company; Tai Tien Pharmaceuticals
- Class Antihyperglycaemics; Cardiovascular therapies; Glucosides; Heart failure therapies; Obesity therapies; Small molecules; Thiophenes
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diabetic nephropathies; Type 2 diabetes mellitus
- Phase III Heart failure
- Phase II Obesity; Type 1 diabetes mellitus
Most Recent Events
- 15 Mar 2024 Registered for Diabetic nephropathies in Japan (PO)
- 04 Mar 2024 Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo company plans to terminate its marketing agreement for Canagliflozin in Japan on September 02, 2024
- 20 Sep 2023 Janssen completes a phase-III trial in Type-2 diabetes mellitus (In children, In adolescents) in USA, Brazil, China, Greece, India, Malaysia, Philippines Mexico, Russia, and Poland (PO) (NCT03170518)